Literature DB >> 32193176

Treatment failure after multiple courses of triclabendazole in a Portuguese patient with fascioliasis.

Elsa Alves Branco1, Rogerio Ruas1, João Nuak1, António Sarmento2.   

Abstract

Fascioliasis is a trematode flatworm infection caused by Fasciola hepatica Humans are incidental hosts, and the infection is most often acquired by eating watercress grown in contaminated water in livestock-rearing areas. Triclabendazole is the only highly effective treatment, with a reported cure rate of >90%. Treatment failure may be due to several factors, though resistance is rare in humans and scarcely reported, most probably a reflection of the widespread use of anthelmintics in livestock. There are three papers describing cases of treatment failure, possibly due to resistance, in the Netherlands, Chile and Peru. We document for the first time one case of failure after multiple treatment courses with triclabendazole in Portugal, probably due to resistance to the anthelmintic. Our aim is to alert for the emergence of resistance across continents, with consequent predictable difficulties in the management of the disease and encourage more investigation in the field. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  hepatitis and other GI infections; infectious diseases

Mesh:

Substances:

Year:  2020        PMID: 32193176      PMCID: PMC7101001          DOI: 10.1136/bcr-2019-232299

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

Review 1.  Epidemiology of fascioliasis in human endemic areas.

Authors:  S Mas-Coma
Journal:  J Helminthol       Date:  2005-09       Impact factor: 2.170

Review 2.  Triclabendazole for the treatment of fascioliasis and paragonimiasis.

Authors:  Jennifer Keiser; Dirk Engels; Gottfried Büscher; Jürg Utzinger
Journal:  Expert Opin Investig Drugs       Date:  2005-12       Impact factor: 6.206

3.  Clinical presentation and management of Fasciola hepatica infection: single-center experience.

Authors:  Muhsin Kaya; Remzi Beştaş; Sedat Cetin
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

4.  [Resistant human fasciolasis: report of four patients].

Authors:  Luis Carlos Gil; Alex Díaz; Carlos Rueda; Christian Martínez; Douglas Castillo; Werner Apt
Journal:  Rev Med Chil       Date:  2014-10       Impact factor: 0.553

Review 5.  Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis.

Authors:  Hector H Garcia; Pedro L Moro; Peter M Schantz
Journal:  Curr Opin Infect Dis       Date:  2007-10       Impact factor: 4.915

6.  Effect of the P-glycoprotein inhibitor, R(+)-verapamil on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  J Savage; M Meaney; G P Brennan; E Hoey; A Trudgett; I Fairweather
Journal:  Vet Parasitol       Date:  2013-03-22       Impact factor: 2.738

7.  A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam.

Authors:  Tran Tinh Hien; Ng Thanh Truong; Nguyen Hoang Minh; Hoang Dinh Dat; Nguyen Thi Dung; Nguyen Thi Hue; Tran Kim Dung; Phung Quoc Tuan; James I Campbell; Jeremy J Farrar; Jeremy N Day
Journal:  Am J Trop Med Hyg       Date:  2008-03       Impact factor: 2.345

Review 8.  Current Threat of Triclabendazole Resistance in Fasciola hepatica.

Authors:  Jane M Kelley; Timothy P Elliott; Travis Beddoe; Glenn Anderson; Philip Skuce; Terry W Spithill
Journal:  Trends Parasitol       Date:  2016-04-02

9.  Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials.

Authors:  Jennifer Keiser; Hanan Sayed; Maged el-Ghanam; Hoda Sabry; Saad Anani; Aly el-Wakeel; Christoph Hatz; Jürg Utzinger; Sayed Seif el-Din; Walaa el-Maadawy; Sanaa Botros
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

10.  Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.

Authors:  Annemarie J S Winkelhagen; Theo Mank; Peter J de Vries; Robin Soetekouw
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

View more
  1 in total

Review 1.  Human Fascioliasis: Current Epidemiological Status and Strategies for Diagnosis, Treatment, and Control.

Authors:  Maria Alejandra Caravedo; Miguel Mauricio Cabada
Journal:  Res Rep Trop Med       Date:  2020-11-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.